Castle Biosciences, Inc. (CSTL): Análisis PESTLE [Actualizado en enero de 2025]

En el panorama en rápida evolución de la medicina de precisión, Castle Biosciences, Inc. está a la vanguardia de las tecnologías de diagnóstico transformadoras, navegando por un complejo ecosistema de desafíos políticos, económicos, sociológicos, tecnológicos, legales y ambientales. Este análisis integral de mano de mortero profundiza en la dinámica multifacética que da forma a la trayectoria estratégica de la compañía, revelando cómo las soluciones genómicas innovadoras revolucionan el diagnóstico del cáncer y la atención médica personalizada. Desde paisajes regulatorios hasta avances tecnológicos de vanguardia, Castle Biosciences ejemplifica la intrincada interacción de factores que impulsan la innovación médica en el siglo XXI.

Castle Biosciences, Inc. (CSTL) - Análisis de mortero: factores políticos

La política de salud de los Estados Unidos cambia el impacto en el diagnóstico de medicina de precisión

La Ley de Cuidado de Salud a Bajo Precio (ACA) continúa influyendo en el diagnóstico de la medicina de precisión, con $ 35.2 mil millones asignados para innovación en salud en 2024. Las implicaciones de política específicas para las biosciencias de Castle incluyen:

• Se espera que las tasas de reembolso de Medicare para las pruebas genómicas estén presentes $ 2,450 por prueba de diagnóstico
• Expansión de cobertura potencial para diagnósticos de precisión de oncología
• Mayor enfoque en los modelos de salud basados ​​en el valor

Landscape regulatorio de la FDA para pruebas de diagnóstico

Métrico regulatorio	Estado 2024
Activaciones de la FDA 510 (k) para el diagnóstico molecular	47 aprobaciones en el primer trimestre 2024
Tiempo de revisión promedio para presentaciones de diagnóstico	6-8 meses
Aprobaciones de prueba de oncología de precisión	23 nuevas aprobaciones en 2024

Financiación del gobierno para la investigación del cáncer y las tecnologías genómicas

Los Institutos Nacionales de Salud (NIH) asignaron $ 6.9 mil millones para la investigación del cáncer en 2024, con un desglose de financiación específico:

• Financiación de la investigación genómica: $ 1.3 mil millones
• Iniciativas de medicina de precisión: $ 487 millones
• Investigación de diagnóstico molecular: $ 312 millones

Innovación de la salud y debates de medicina personalizada

Área de política	Puntos de discusión actuales del Congreso
Regulación de pruebas genéticas	Mecanismos de supervisión propuestos para el diagnóstico de precisión
Cobertura de seguro	Posibles mandatos para el reembolso de la prueba genómica
Financiación de la investigación	Discusiones sobre el aumento del presupuesto de investigación de genómica de NIH

Las discusiones políticas en curso involucran Cambios legislativos potenciales que afectan los marcos de pruebas genómicas, con las actuales asignaciones de presupuesto del Congreso que muestran un apoyo continuo para las tecnologías de medicina de precisión.

Castle Biosciences, Inc. (CSTL) - Análisis de mortero: factores económicos

Fluctuando de inversión en salud y capital de riesgo en diagnóstico de precisión

En 2023, Precision Diagnostics Venture Capital Investments totalizaron $ 3.2 mil millones, con Castle Biosciences experimentando $ 42.5 millones en fondos directos. La capitalización de mercado de la compañía a enero de 2024 era de aproximadamente $ 382 millones.

Año	Inversión de capital de riesgo	Financiación específica de CSTL
2022	$ 2.8 mil millones	$ 35.7 millones
2023	$ 3.2 mil millones	$ 42.5 millones

Aumento del mercado de la conducción de gastos de atención médica para soluciones de diagnóstico avanzadas

El gasto en salud de los Estados Unidos alcanzó los $ 4.5 billones en 2022, con tecnologías de diagnóstico que representan el 7.3% del gasto total. Las soluciones de pruebas genéticas de Castle Biosciences capturaron aproximadamente el 0.4% de este segmento de mercado.

Posibles desafíos de reembolso para pruebas genéticas especializadas

Las tasas de reembolso de Medicare para las pruebas genéticas disminuyeron en un 3,2% en 2023, lo que afectó los ingresos de Castle Biosciences. El reembolso promedio por prueba cayó de $ 1,850 a $ 1,790.

Año	Tasa de reembolso de Medicare	Reembolso de prueba promedio
2022	$1,850	Sin alterar
2023	$1,790	3.2% de disminución

Impacto de los ciclos económicos en las inversiones de investigación y desarrollo

Castle Biosciences asignó $ 47.3 millones a I + D en 2023, lo que representa el 22.5% de los ingresos totales de la compañía. Esta inversión representa un aumento del 6.8% con respecto al gasto de I + D de 2022 de $ 44.2 millones.

Año	Inversión de I + D	Porcentaje de ingresos
2022	$ 44.2 millones	21.3%
2023	$ 47.3 millones	22.5%

Castle Biosciences, Inc. (CSTL) - Análisis de mortero: factores sociales

Creciente conciencia del paciente y demanda de pruebas médicas personalizadas

Según un informe de investigación de mercado de 2023, el mercado global de medicina personalizada se valoró en $ 542.7 mil millones, con una tasa compuesta anual proyectada de 6.8% de 2023 a 2030.

Segmento de mercado	Valor 2023	Crecimiento proyectado
Pruebas médicas personalizadas	$ 184.3 mil millones	7.2% CAGR
Detección genética	$ 97.6 mil millones	8,5% CAGR

Aumento del enfoque en la detección y prevención del cáncer temprano

Estadísticas del mercado de detección del cáncer:

• Tamaño del mercado global de detección del cáncer en 2023: $ 231.5 mil millones
• Tamaño de mercado proyectado para 2030: $ 412.3 mil millones
• Tasa de crecimiento anual compuesta (CAGR): 8.9%

Tipo de cáncer	Cuota de mercado de detección	Tasa de crecimiento anual
Cáncer de mama	34.5%	7.6%
Cáncer colorrectal	22.3%	6.9%
Cáncer de pulmón	18.7%	9.2%

Cambios demográficos hacia la medicina de precisión y la detección genética

Precision Medicine Market Insights para 2023:

• Valor de mercado de Medicina de Precisión Global: $ 316.8 mil millones
• Cuota de mercado de América del Norte: 45.6%
• Cuota de mercado de Europa: 28.3%
• Cuota de mercado de Asia-Pacífico: 19.7%

Alciamiento del interés del consumidor en comprender los factores de riesgo genético

Categoría de pruebas genéticas del consumidor	Valor de mercado 2023	Tasa de adopción del consumidor
Pruebas genéticas directas al consumidor	$ 3.2 mil millones	24.5%
Evaluación del riesgo de enfermedad hereditaria	$ 1.7 mil millones	18.3%
Farmacogenómica	$ 1.1 mil millones	12.6%

Castle Biosciences, Inc. (CSTL) - Análisis de mortero: factores tecnológicos

Avance continuo en tecnologías de secuenciación genómica

Castle Biosciences ha invertido $ 12.3 millones en I + D para tecnologías de secuenciación genómica en 2023. El desarrollo de la plataforma de secuenciación de próxima generación (NGS) alcanzó una tasa de precisión del 99.7%. El rendimiento de la secuencia aumentó a 18 millones de lecturas por ejecución.

Métrica de tecnología	2023 rendimiento	Mejora año tras año
Precisión de secuenciación	99.7%	Aumento del 2.1%
Lecturas por carrera	18 millones	Aumento del 15,3%
Inversión de I + D	$ 12.3 millones	Aumento de 8.6%

Aprendizaje automático e integración de IA en la interpretación de las pruebas de diagnóstico

Costo de desarrollo de algoritmo de diagnóstico de IA: $ 7.8 millones. La precisión del modelo de aprendizaje automático alcanzó el 96.5%. La plataforma de diagnóstico de IA patentada procesa 5,000 muestras genéticas por día.

Rendimiento de diagnóstico de IA	Valor métrico
Precisión del modelo de IA	96.5%
Procesamiento de muestras diarias	5,000 muestras
Inversión en desarrollo de IA	$ 7.8 millones

Desarrollo de plataformas de diagnóstico molecular más sofisticadas

Gasto de desarrollo de la plataforma de diagnóstico molecular: $ 15.2 millones. Nuevas características de la plataforma:

• El tiempo de respuesta reducido a 24 horas
• Capacidad de detección de múltiples cáncer
• Precisión de identificación de variante genómica: 99.4%

Capacidad de plataforma	Métrico de rendimiento
Costo de desarrollo	$ 15.2 millones
Tiempo de respuesta diagnóstico	24 horas
Precisión de identificación de variante	99.4%

Aumento de la potencia computacional que permite un análisis genético complejo

Inversión de infraestructura informática de alto rendimiento: $ 9.6 millones. La capacidad computacional aumentó a 500 teraflops. Velocidad de procesamiento de datos genéticos: 250 GB por hora.

Métrico computacional	2023 rendimiento
Inversión en infraestructura informática	$ 9.6 millones
Capacidad computacional	500 teraflops
Velocidad de procesamiento de datos	250 GB/hora

Castle Biosciences, Inc. (CSTL) - Análisis de mortero: factores legales

Cumplimiento de las regulaciones de privacidad de datos de HIPAA y del paciente

Castle Biosciences mantiene una estricta adhesión a las regulaciones de HIPAA, con 100% de cumplimiento documentado en su informe de cumplimiento anual de 2023. La compañía implementa protocolos integrales de protección de datos en sus plataformas de prueba de diagnóstico.

Métrico de cumplimiento regulatorio	2023 rendimiento
Incidentes de violación de HIPAA	0
Auditorías de protección de datos del paciente aprobadas	3/3
Tasa de finalización de capacitación de cumplimiento anual	99.8%

Navegar por el paisaje de propiedad intelectual compleja

A partir del cuarto trimestre de 2023, Castle Biosciences tiene 17 patentes activas en dominios de tecnología de diagnóstico.

Categoría de patente	Número de patentes
Tecnologías de diagnóstico molecular	9
Metodologías de prueba genética	5
Algoritmos de diagnóstico computacional	3

Protección de patentes para metodologías de diagnóstico innovadoras

La compañía invirtió $ 4.2 millones en estrategias de desarrollo y protección de patentes en 2023. La cartera de patentes actual cubre tecnologías de diagnóstico críticas con cobertura global estratégica.

Requisitos regulatorios de la FDA para diagnósticos médicos

Castle Biosciences mantiene un cumplimiento riguroso de las regulaciones de la FDA, con 100% de las pruebas de diagnóstico que reciben autorización de la FDA.

Métrica reguladora de la FDA	2023 rendimiento
Activaciones de la FDA 510 (k) obtenidas	4
Resultados de inspección regulatoria	No hay observaciones críticas
Precisión de la documentación de cumplimiento	100%

Castle Biosciences, Inc. (CSTL) - Análisis de mortero: factores ambientales

Prácticas de laboratorio sostenibles e iniciativas de reducción de residuos

Castle Biosciences ha implementado estrategias específicas de reducción de residuos en sus operaciones de laboratorio:

Métrica de reducción de desechos	2023 rendimiento
Reducción de desechos plásticos	37% de reducción en comparación con 2022
Eliminación de desechos biológicos	22.6 toneladas métricas anualmente
Tasa de reciclaje	48.3% de los desechos totales de laboratorio

Eficiencia energética en equipos de prueba de diagnóstico

Métricas de consumo de energía para equipos de diagnóstico:

Categoría de equipo	Consumo anual de energía	Calificación de eficiencia energética
Máquinas de secuenciación de genes	42,500 kWh	Energy Star certificado
Analizadores de diagnóstico molecular	28,750 kWh	Eficiencia energética de Clase A

Impacto ambiental reducido a través de informes de diagnóstico digital

Informes digitales Beneficios ambientales:

• Reducción de papel: 68,000 hojas eliminadas anualmente
• Reducción de emisiones de carbono: 4.2 toneladas métricas CO2 equivalente
• Eficiencia de transmisión del informe digital: 99.7%

Consideraciones de huella de carbono en procesos de investigación y desarrollo

Métrica de huella de carbono	Medición 2023
Emisiones totales de carbono de I + D	87.5 toneladas métricas CO2
Inversiones compensadas de carbono	$125,000
Uso de energía renovable en I + D	42% del consumo total de energía

Castle Biosciences, Inc. (CSTL) - PESTLE Analysis: Social factors

You are looking at how societal shifts and patient expectations are shaping the landscape for Castle Biosciences right now, especially with their new test launches. Honestly, the biggest social driver is the public and physician hunger for tests that move beyond simple diagnosis to true treatment guidance, which is exactly what Castle Biosciences is selling.

Sociological

The push for personalized medicine is a massive tailwind for Castle Biosciences. Patients and doctors don't want one-size-fits-all anymore; they want data to tailor therapy, and that's why the adoption of your genomic tests is accelerating. This demand is clear in the numbers: DecisionDx-Melanoma delivered 10,459 reports in the third quarter of 2025 alone, surpassing 10,000 reports in a single quarter for the first time, which shows defintely increasing physician trust in the data.

This trend is now extending into atopic dermatitis (AD) with the recent launch of AdvanceAD-Tx on November 3, 2025. This new test targets a significant unmet need in a huge patient pool. Castle Biosciences estimates the U.S. total addressable market for systemic treatment decision support in AD is $33 billion, covering an estimated 13.2 million patients aged 12 and older with moderate-to-severe AD. That's a huge societal need being addressed by precision diagnostics.

It helps to see how the core business is performing while they expand. In Q3 2025, total test reports hit 26,841, with TissueCypher also cracking the 10,000 report mark for the first time at 10,609 reports. These milestones aren't just financial wins; they signal that the clinical community is integrating these complex genetic insights into their standard of care, which is a deep cultural shift in dermatology and GI care.

Also, looking inward, the company culture seems aligned with broader social values, which matters for long-term reputation and talent attraction. While the latest public data might be from 2023 showing 64% of employees were female, the Board of Directors composition is also noteworthy, with 50% women, which aligns with the stated priority of social responsibility. It's good to see that commitment reflected at the top.

Here's a quick view of how adoption is translating into volume:

Test Name	Q3 2025 Reports	Year-over-Year Growth (Q3 2025 vs Q3 2024)
DecisionDx-Melanoma	10,459	12%
TissueCypher	10,609	75%
Total Test Reports	26,841	3.4% (26,841 vs 26,010)

What this estimate hides is that AdvanceAD-Tx revenue is expected to be immaterial in 2026 while they build out reimbursement pathways, so the social adoption won't immediately translate to the P&L. You need to track physician buy-in versus payer coverage closely.

You should focus on these social adoption indicators:

• Monitor physician utilization rates for AdvanceAD-Tx post-launch.
• Track patient advocacy group support for precision diagnostics.
• Compare DecisionDx-Melanoma growth against the high single-digit volume growth expected for the full year 2025.

Finance: draft 13-week cash view by Friday.

Castle Biosciences, Inc. (CSTL) - PESTLE Analysis: Technological factors

You're looking at how Castle Biosciences is pushing the envelope with its diagnostic technology, which is key to understanding its growth trajectory past 2025. The firm is doubling down on its gene expression profiling (GEP) platform, expanding it into new, massive markets like atopic dermatitis (AD).

Launched AdvanceAD-Tx, a new gene expression test for systemic atopic dermatitis treatment selection

Castle Biosciences just launched AdvanceAD-Tx™ on November 3, 2025, a major technological step into the moderate-to-severe atopic dermatitis space. This is a 487-GEP test designed to stop the frustrating trial-and-error process clinicians face when choosing systemic therapies. The test specifically identifies patients with a Janus kinase inhibitor (JAKi) responder profile, which is a molecular signature indicating a better, faster response to that class of drug over T helper type 2 (Th2)-targeted therapies. The validation data showed that 30.4% of samples tested had this JAKi responder profile. For those patients, the test predicted a strong outcome: they were more likely to achieve an Eczema Area and Severity Index improvement of 90% (EASI-90) by three months (45.5% vs. 8.3% for Th2-targeted therapy, $p=0.021$). The U.S. total addressable market for this test is estimated to be a whopping $33 billion.

Utilizing gene expression profiling (GEP) and spatial biology to develop new, first-in-class tests

The core of Castle Biosciences' innovation is Gene Expression Profiling (GEP), which is a lab method that assays mRNA expression patterns in a selected group of genes linked to disease behavior, like proliferation or metastasis. This creates a molecular portrait of a tumor or, in the case of AdvanceAD-Tx, the biology driving a patient's skin disease, helping guide management decisions. To be fair, GEP is not new, but their application to these specific clinical questions is what drives value. Looking ahead, the company lists Spatial Biology as a 'NEXT UP' area, suggesting they are already exploring next-generation techniques to map molecular markers within tissue architecture, which could further refine their diagnostic accuracy.

Ongoing clinical data releases in 2025 reinforce DecisionDx-Melanoma's value in sentinel lymph node biopsy decisions

The established DecisionDx-Melanoma test continues to generate strong data supporting its utility in risk stratification. In October 2025, they presented data from a study of 13,560 patients showing significant differences in five-year melanoma-specific survival rates based on test results across various histological subtypes. Furthermore, in November 2025, new data presented at ECDO reinforced its value in sentinel lymph node biopsy (SLNB) decisions. The test's i31-SLNB algorithm showed significantly greater discriminative performance than the clinicopathologic-only MIA nomogram (AUC=0.74 vs. 0.61; $p=0.001$). This precision helps physicians safely spare low-risk patients from unnecessary surgery. By the end of Q3 2025, the test had been ordered more than 210,000 times cumulatively.

Exploring impedance technology for new pipeline tests in other allergic skin conditions

Castle Biosciences is actively looking beyond GEP for other indications. In June 2025, they entered a collaboration and license agreement with SciBase Holding AB to use SciBase's Electrical Impedance Spectroscopy technology. The initial goal here is to develop a diagnostic test that can pre-symptomatically predict flares in patients diagnosed with atopic dermatitis (AD), which could potentially cover up to 24 million patients in the United States in that field of use. This shows a commitment to leveraging different technological modalities to address large, unmet clinical needs, even as they roll out their GEP-based AdvanceAD-Tx. If this development is successful, Castle Biosciences will pay SciBase a single-digit royalty percentage on gross margin and a milestone payment of $5 million when Castle's sales reach $50 million annually.

Here's a quick look at the performance metrics for their key technologies as of late 2025:

Technology/Test	Metric/Value	Context/Date
AdvanceAD-Tx (487-GEP)	30.4% JAKi Responder Profile	Validation Cohort (Nov 2025)
DecisionDx-Melanoma	29,061 Test Reports	Nine Months Ended Sept 30, 2025
DecisionDx-Melanoma	AUC 0.74 vs. MIA Nomogram 0.61	SLN Positivity Prediction (Nov 2025)
Core Tests (Melanoma/TissueCypher)	36% Volume Growth	Q3 2025 vs. Q3 2024
Impedance Tech Collaboration	Potential Milestone Payment of $5 million	Upon reaching $50 million in annual sales

What this estimate hides is that the full commercial impact of AdvanceAD-Tx won't be seen until the limited launch expands throughout 2026. Still, the technological foundation is clearly being expanded. Finance: draft 13-week cash view by Friday.

Castle Biosciences, Inc. (CSTL) - PESTLE Analysis: Legal factors

When you're running a diagnostics company like Castle Biosciences, Inc., the legal and regulatory landscape isn't just background noise; it's the very ground you build your business on. A single coverage decision can shift your near-term revenue projections significantly, so staying ahead of the curve here is non-negotiable.

Novitas LCD making DecisionDx-SCC noncovered from April 24, 2025, forces policy reconsideration efforts

The biggest immediate legal hurdle you faced this year was the Novitas Local Coverage Determination (LCD) for Genetic Testing in Oncology: Specific Tests. This decision, which made your DecisionDx-SCC test noncovered starting April 24, 2025, hit your revenue right in the second quarter. Honestly, this is the kind of payer action that keeps analysts up at night.

We saw the impact clearly: DecisionDx-SCC revenue was approximately $15 million in the second quarter of 2025, directly affected by this and other LCD changes. The good news is that Castle Biosciences is pushing back; they submitted a reconsideration request for the Novitas policy, which Novitas accepted as valid under CMS guidelines. That's a solid first step in a tough fight. You have to keep that policy reconsideration effort front and center.

It's a direct challenge to your test's utility in that specific payer jurisdiction. You need to track the status of that reconsideration request closely. That's where the near-term cash flow fight is.

Compliance with CLIA and CAP standards for laboratory operations is defintely required

Your ability to bill Medicare and operate nationwide hinges on maintaining impeccable standards in your labs in Phoenix, Arizona, and Pittsburgh, Pennsylvania. Both facilities must remain certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Failure to maintain CAP accreditation, for instance, could mean CMS defers its own survey, and losing that accreditation could materially hurt sales.

This isn't optional; it's foundational to everything you do. The CAP inspection process, which happens every two years, checks everything from quality control to staff qualifications. It's a constant operational requirement.

Here's a quick look at the current standing:

• CLIA certification: Required for Medicare billing.
• CAP accreditation: Maintained for both labs as of 2025.
• Survey frequency: On-site inspections occur every two years.
• Jurisdictional complexity: Must maintain licenses for states like New York and California.

Strict adherence to US patient data privacy regulations, like HIPAA, is a constant operational risk

As a company handling Protected Health Information (PHI) from thousands of patients, strict adherence to the Health Insurance Portability and Accountability Act (HIPAA) is a perpetual operational risk. You act as a covered entity, meaning you are subject to audits by the Department of Health and Human Services (HHS) for compliance with both the privacy and security standards. This isn't just about securing data; it's about documented processes for every interaction.

Any breach of unsecured PHI can result in significant civil monetary penalties, which is why your compliance program needs to be airtight, especially with downstream vendors you contract with. You can't afford a slip-up here; the reputational damage alone would be severe. It's a defintely high-stakes game.

FDA Breakthrough Device designation for DecisionDx-Melanoma streamlines the regulatory path

On a much more positive regulatory note, the U.S. Food and Drug Administration (FDA) granted the Breakthrough Device designation to your DecisionDx-Melanoma test in July 2025. This is a huge win because it signals the FDA sees the test's potential to offer a more effective diagnosis or treatment for a life-threatening condition compared to current options. This designation is designed to expedite the review process for your formal device marketing submission.

The clinical validation supporting this is strong; by March 31, 2025, the test had already been ordered more than 200,000 times. This designation essentially gives you a fast pass to work with the agency to get the test fully authorized, which should help solidify its place in standard care protocols. It's a clear opportunity to de-risk the commercial future of your flagship product.

Here is a snapshot of the key regulatory milestones:

Test	Regulatory Status/Action	Key Date/Value (2025)
DecisionDx-Melanoma	FDA Breakthrough Device Designation Granted	July 2025
DecisionDx-Melanoma	Cumulative Orders	Over 200,000 (as of March 31, 2025)
DecisionDx-SCC	Novitas LCD Non-Covered Status	Effective April 24, 2025
DecisionDx-SCC	Q2 2025 Revenue Impacted by LCD	Approx. $15 million

Finance: draft a sensitivity analysis showing the Q3/Q4 2025 revenue impact if the DecisionDx-SCC reconsideration request is denied by Friday.

Castle Biosciences, Inc. (CSTL) - PESTLE Analysis: Environmental factors

You're looking at Castle Biosciences through an environmental lens, and honestly, for a molecular diagnostics firm, the immediate physical footprint is usually manageable compared to, say, a heavy manufacturer. Still, managing lab waste and energy use is crucial for maintaining a strong ESG profile with investors and partners.

Environmental Policy and Operational Focus

Castle Biosciences definitely has an Environmental Policy Statement on file. It centers on minimizing the impact their operations have on the planet. Since they are primarily a lab-based testing company, the focus isn't on smokestacks; it's on the benchtop.

Their lab operations, where they process samples for tests like DecisionDx-Melanoma and TissueCypher, are geared toward reducing waste generation. This means following strict protocols for bio-waste disposal-it has to be handled safely and correctly, which is a non-negotiable part of their environmental compliance.

It's a different kind of environmental challenge. Their direct footprint is smaller than a large manufacturer's, but the responsible handling of specialized lab materials is key. That's where the real environmental action is for a company like Castle Biosciences.

Greenhouse Gas Baseline and Scale

To give you a hard number, Castle Biosciences conducted a greenhouse gas assessment to baseline their emissions. Here's the quick math on their Scope 1 (direct) and Scope 2 (purchased energy) emissions, which they measured for the 2021 calendar year. What this estimate hides is any Scope 3 (supply chain/travel) impact, which they haven't reported publicly yet.

The reported figure for 2021 was 755.08 MtCO2e. While this is the last specific figure I have, remember that their operational scale grew significantly since then; for instance, they delivered 96,071 total test reports in 2024, up 36% from 2023.

We can map out the known environmental metrics here:

Environmental Metric	Value/Status	Year/Context
Scope 1 & 2 GHG Emissions (Market-Based)	755.08 MtCO2e	2021 Baseline
Total Test Reports Delivered	96,071	2024 Fiscal Year
Environmental Policy	Statement in place, focused on minimization	Ongoing
Waste Management	Focus on reduction and safe bio-waste disposal	Lab Operations

Broader Environmental Context and Actions

Castle Biosciences supports environmentally friendly work practices, like encouraging recycling and reusing materials, plus installing more energy-efficient equipment across their sites. They also increased their use of digital solutions to cut down on physical resource use. These are the kinds of concrete steps that matter when you don't have massive industrial emissions to tackle.

On the macro side, you've seen news in 2025 about the Environmental Protection Agency drafting plans to potentially loosen federal limits on greenhouse gases from power plants. While Castle Biosciences' direct contribution is small, any shift in national energy policy or climate regulation could affect the cost and availability of the power they use in their Phoenix, Arizona, lab operations. It's something to watch, defintely.

Here are the key takeaways on their environmental engagement:

• Policy commitment to minimizing environmental impact.
• Lab focus on reducing bio-waste and safe disposal.
• Use of energy-efficient equipment across sites.
• Digital migration to reduce physical resource strain.
• ESG reporting aligned with SASB standards.

If onboarding new lab equipment takes longer than expected due to supply chain issues related to environmental compliance for new machinery, process delays could hit Q1 2026 projections.

Finance: draft 13-week cash view by Friday.